The Patent Finder

Orient Pharma (Samoa) Co., Ltd

Also on record
Records under this name other than patents Orient Pharma (Samoa) Co., Ltd holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 2 of 2 · Back to Orient Pharma (Samoa) Co., Ltd

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,658,683Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
Lapsed on the fee record
Ended Feb 25, 2026 · USPTO record
Lapsed on the fee recordEnded Feb 25, 2026USPTO record
US 8,481,583Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
Lapsed on the fee record
Ended Jul 9, 2025 · USPTO record
Lapsed on the fee recordEnded Jul 9, 2025USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited